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INTRODUCTION
Bacterial contamination of breast implants can cause in-
fection,1 capsular contracture (CC),2–4 and has been linked 
to breast implant-associated anaplastic large cell lymphoma 
(BIA-ALCL).5 Bacteria can also be identified on clinically be-
nign breast implants, however, as they indefinitely abut pa-
renchymal tissue laden with a diverse array of microbes.6–10 
Staphylococcus epidermidis is the most common bacterium 
found on both pathologic and nonpathologic implants, yet 
why complications manifest in some women and not oth-
ers remains unknown.11 To establish the impact of bacterial 
contamination, including differing bacterial species, strains, 
abundance, or virulence factors, on breast implant patholo-
gy, detailed characterization of bacteria on clinically benign 
breast implants is needed to establish a negative control 
against which pathology can be compared.
The majority of bacterial infections of medical devices 
are associated with biofilms. Hallmarks of these infec-
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tions include increased resistance to antibiotics and the 
host immune system, resulting in chronic infection, treat-
ment failure, and often surgical intervention.12 For breast 
implants bacterial biofilm formation is a major concern. 
There is a large unmet need to understand the mecha-
nisms by which bacteria colonize breast implants to form 
biofilms to develop effective drugs that can eradicate 
biofilm-associated infections. The extent to which bacte-
ria become associated with breast implants is influenced 
by the surface characteristics of the device.13–15 Textured 
devices, whose contoured surfaces have increased surface 
area available for bacterial colonization, harbor signifi-
cantly more bacteria than do smooth breast implant sur-
faces.16 However, recent studies show that medical devices 
become coated with host proteins that can be exploited by 
bacterial pathogens for colonization and biofilm forma-
tion.11,17 For example, Staphylococcus aureus, which causes 
the majority of implant-associated infections (IAI), utilizes 
a fibrinogen binding adhesin to colonize devices that be-
come coated with fibrinogen, a common occurrence after 
placement of most kinds of medical devices.18,19 For breast 
prostheses, additional host ligands are deposited on the 
devices in the form of a collagen-rich capsule and this 
likely facilitates bacterial colonization.20,21 A granular un-
derstanding of the host-pathogen interactions that lead to 
breast implant colonization and the biological signals that 
trigger the switch from a benign to a pathologic state will 
inform future strategies to optimize breast implant design 
and establish antibiotic-sparing therapies that prevent 
problematic bacterial contamination.19,22–25
The purpose of this observational study is 2-fold: (1) we 
examined the extent of which bacteria were associated with 
a series of explanted breast prostheses, with different surface 
characteristics, obtained from normal and pathologic clini-
cal scenarios and used immunofluorescence techniques to 
characterize the bacteria associated with the devices; and 
(2) we evaluate, for the first time, matrix protein deposi-
tion on the breast device surface to determine the potential 
repertoire of available bacterial binding ligands. Character-
ization of bacterial binding mechanisms to breast implants 
may lead to the development of nonantibiotic antibacterial 
therapeutics for downstream clinical translation.
METHODS
Study Population
Cosmetic or reconstructive breast prostheses, either 
implants or tissue expanders (TE), explanted between 
March 2017 and March 2018 were analyzed under proto-
col #201703063 at the Washington University School of 
Medicine. We identified patients with CC, double capsules, 
seroma, and infection. Benign breast prostheses consisted 
of TE removed at the time of planned device exchange 
as well as the contralateral breast implant in patients with 
unilateral pathology where both devices were explanted. 
Breast prostheses and capsules were sharply removed us-
ing sterile technique, the surface between capsule and 
implant was marked with a suture, and samples were sec-
tioned and immediately placed in a sterile container. In all 
cases, the entire breast prosthesis was removed, while the 
entire capsule was removed in cases of CC and double cap-
sules, while the submuscular capsule was entirely removed 
but the acellular dermal matrix sling maintained in cases 
of submuscular TEs. In this manner, >25 sq cm of capsule 
and implant surface was made available for analysis. De-
vice type was confirmed to be consistent with the medical 
record. Duration of implantation, device type, and clinical 
presentation were recorded.
Bacterial Culture and Identification
Explanted devices were divided into 3 sections, the larg-
est section (>25 sq cm) was fixed for immunofluorescence 
staining and the 2 smaller pieces (~4–25 sq mm) were cul-
tured for bacterial growth. One piece was sonicated for 10 
minutes in phosphate buffered saline, plated on the rich 
media Brain Heart Infusion agar, and grown aerobically 
and anerobically at 37°C for 48 hours. Individual bacterial 
species were evaluated for colony size, morphology, color, 
and bacterial load. The second piece was submerged in 
BHI and grown for 48 hours at 37°C. Cultures with vis-
ible microbial growth were restreaked onto BHI agar for 
single colonies. A representative isolate of each bacterial 
species was selected for identification via 16S sequencing, 
as described previously.18
Immunofluorescence Staining
Immunofluorescence staining was performed as previ-
ously described.18 Briefly, the largest piece of the patient 
device was fixed, blocked, washed, and incubated with 
primary antibodies. Devices were then washed and incu-
bated with secondary antibodies, which were then washed, 
dried, and imaged. All antibodies were tested against each 
isolated bacterial species to determine the optimal con-
centration for immunofluorescence detection. Infrared 
signal was examined using the Odyssey Imaging System 
(LI-COR Biosciences, Lincoln, Nebraska). Controls for 
auto-fluorescence included small pieces of each respec-




Twenty-two clinically benign and 18 clinically patho-
logic breast prostheses were explanted from 33 women. 
Half of the breast prostheses placed were for reconstruc-
tive cases and the other half were for cosmetic purposes. 
Duration of implantation ranged from 3 months for 
some TEs to 540 months for severely contracted smooth, 
shaped, saline filled Dow Corning breast implants. Pocket 
irrigation with 50% Betadine26 was utilized in the TE cases, 
but this information was not reliably available for the oth-
er implants collected.
Bacteria Cultured from Benign Breast Implants
Patient samples were cultured to determine the bacte-
rial abundance (Table 1), and 16S sequencing was utilized 
to identify the species (Fig. 1 and Supplemental Digital 
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Content 1) colonizing uncomplicated devices (see figure, 
Supplemental Digital Content 1, which displays presence, 
absence, and species of bacteria identified on breast im-
plants explanted from women in the absence of clinical 
pathology. Results from analyses for bacteria from TEs, 
permanent breast implants (I), capsules (CAP), http://
links.lww.com/PRSGO/A930). Bacteria were cultured 
from 9 of 22 clinically normal explanted devices or peri-
prosthetic capsules, including 6 of 15 (40%) Biocell TEs 
and 3 of 4 (75%) Biocell textured implants. In instances 
where bacteria were recovered, more than one species was 
identified in 6 of 9 breasts (Supplemental Digital Content 
1). Only Gram-positive bacteria, and specifically coagulase-
negative staphylococci (CNS), were detected on clinically 
normal breast implants. In contrast, clinically normal TE 
were colonized by a broader array of both Gram-positive 
and Gram-negative bacteria. CNS, Klebsiella pneumoniae, 
Pseudomonas aeruginosa, and Enterobacter, were recovered 
from 4 Biocell textured TE implanted for 124, 157, 180, 
and 372 days (Supplemental Digital Content 1). Bacteria 
were not detected on the 3 clinically normal saline and 
Siltex textured breast implants evaluated (Fig. 1 and Sup-
plemental Digital Content 1). Additionally, while capsular 
tissue was not routinely harvested for all specimens, there 
were 2 instances, one with a TE and one with an implant, 
where bacteria were retrieved from the prosthesis but not 
the capsule (Supplemental Digital Content 1).
Bacteria Cultured from Pathologic Breast Implants
Clinically complicated samples were cultured and 
bacterial abundance was assessed (Table 1) and species 
colonizing pathologic prostheses were determined via 
16S sequencing (Fig. 1 and Supplemental Digital Con-
tent 1). CCs were noted in 12 breast prostheses collected 
from 8 women (Fig. 1 and Supplemental Digital Content 
2) and S. epidermidis was identified in the majority (67%) 
of these cases (see figure, Supplemental Digital Content 
2, which displays presence, absence, and species of bacte-
ria identified on breast implants explanted from women 
in the absence of clinical pathology. Pathology catego-
rized as CC, double capsule without seroma (seroma (-)
ve), double capsule with seroma (seroma (+)ve), or in-
fection requiring explantation, http://links.lww.com/
PRSGO/A990). Other Gram-positive bacteria, including 
other CNS, were found colonizing the rest (Supplemen-
tal Digital Content 2). Smooth-surface and Siltex and 
Biocell textured devices (both saline and silicone) were 
represented in the CCs analyzed (Fig. 1). Bacteria were 
inconsistently identified in smooth and textured devices 
complicated by CC (Fig. 1). Double capsules—defined as 
2 distinct capsules between the device and the soft-tissue 
space with 1 capsule tenaciously adherent to the device 
surface—were exclusively identified in patients with Bio-
cell textured prostheses (Fig. 1). CNS were identified in 
2 of the 5 double capsules with or without seroma (Fig. 1 
and Supplemental Digital Content 2). One TE was ex-
planted for infection, and CNS was isolated (Fig. 1 and 
Supplemental Digital Content 2). Interestingly, the mi-
crobes isolated from the complicated prostheses were 
exclusively Gram-positive bacteria.
Matrix Protein Deposition on Breast Implants
Complicated (n = 5) and normal (n = 13) devices with-
out any detectable bacteria were immunofluorescently 
stained for the presence of host proteins, including fibrin-
ogen, a protein known to be deposited on other medical 
devices,18,22,27 and collagen type I and type III, proteins that 
make up the implant capsule.21,28,29 Fibrinogen was present 
on 5/5 and 12/13 clinically complicated and normal devices 
(Table 2 and Fig. 2). Collagen was detected on 4/5 and 9/13 
clinically complicated and normal devices. All analyzed tex-
tured devices, including 14 Biocell and 2 Siltex, were coated 
with fibrinogen. Smooth surfaced breast implants4 included 
1 that lacked matrix protein deposition, 1 coated with fibrin-
ogen, and 2 coated with fibrinogen and collagen.
Bacteria Co-localize with Deposited Matrix Proteins
Breast prostheses with detectable bacteria16 were im-
munofluorescently stained with commercially available 
antibodies for the respective microbe (antibodies were 
not available for Micrococcus, Bacillus, or Exiguobacterium). 
S. epidermidis was detected on all devices from which the 
bacteria were isolated (Table 3). Additionally, since staph-
ylococcal-collagen interactions have been implicated in 
breast IAI,11 we simultaneously stained the samples for col-
lagen. S. epidermidis predominantly co-localized with col-
lagen (Tables 4, 5, Fig. 3). Furthermore, group B strep 
was detected on the device from patient 9 (Supplemental 
Digital Content 2 and Fig. 3) and K. pneumoniae was de-
tected on the prostheses from patient 23 (Supplemental 
Digital Content 2 and Fig. 3). Interestingly, we found that 
group B Strep and K. pneumoniae co-localized with fibrino-
gen (Table 4). Bacteria were not detected on the other 10 
devices via immunofluorescence staining. Overall, of the 
bacteria that could be detected on both clinically normal 
and pathologic Biocell textured and smooth surfaced im-
Table 1. Bacterial Load Recovered from Clinically Normal 
and Complicated Patient Devices








2 Expander 2.0 x 10^0 M. luteus
3.0 x 10^0 S. epidermidis
3 Expander 3.0 x 10^0 CNS
1.3 x 10^1 S. epidermidis
4 Expander 5.9 x 10^1 CNS
3.5 x 10^1 Pseudomonas 
aeruginosa
Capsule 1.69 x 10^3 K. pneumoniae
2.0 x 10^1 E. faecalis
3.1 x 10^2 P. aeruginosa
2.0 x 10^1 CNS
7 Implant 1 x 10^0 S. haemolyticus
1 x 10^0 S. hominis
23 Implant 4.0 x 10^0 S. cohnii
Clinically com-
plicated
22 Implant 1 x 10^0 S. epidermidis
25 Capsule 1.0 x 10^0 S. epidermidis
2.3 x 10^1 CNS
27 Capsule 5.0 x 10^0 S. epidermidis
32 Left 1.3 x 10^1 Staphylococcus 
epidermidis
CFU, colony forming units.
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plants, all were found to co-localize with matrix proteins 
(Tables 4, 5, Fig. 3).
DISCUSSION
Bacteria cause IAI,1 have a role in CC,2,3,30–32 and may 
play a role in the etiology of BIA-ALCL5; however, the 
microbial species responsible and the host-pathogen 
interactions that result in these diverse complications 
are still being investigated. We have previously shown 
that the predominant Gram-positive and Gram-neg-
ative bacterial causes of breast IAI and explantation 
are S. aureus and P. aeruginosa, respectively.1 Ralstonia 
pickettii has also been identified in a disproportion-
ately high percentage of breast implants from patients 
with BIA-ALCL.5 Additionally, while there is a grow-
ing body of evidence implicating bacterial coloniza-
Table 2. Clinically Normal Breast Implants without 






1 I Smooth + ˗
6 TE Biocell texture + +
8 TE Biocell texture + +
11 TE Biocell texture + ˗
12 TE Biocell texture + +
13 TE Biocell texture + +
17 I Siltex texture + +
18 I Smooth ˗ ˗
19 TE Biocell texture + +
20 TE Biocell texture + ˗
21 TE Biocell texture + +
23 TE Biocell texture + +
24 I Smooth + +
Fig. 1. Schematic categorization of study implants by presence or absence of pathology, presence or absence of implant or capsular bac-
teria, and implant type. Pathology includes cc, double capsule with or without intervening seroma, and infection requiring explantation.
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tion of devices in the development of CC, including a 
strong correlation between Baker grade and positive 
breast implant and TE cultures3 and a  reduction in 
CC rates after breast implant placement with the use 
of  antibiotic pocket irrigation or impregnated mesh 
strategies,32–35 these findings are not universally consis-
tent among reports,36,37 and the latter are limited to a 
mean of 2 years of follow-up or less.33–35 An elegant swine 
model, however, has demonstrated causation between 
S. epidermidis infection and CC.2 Together, these stud-
ies highlight the need to better understand the host-
pathogen interactions that facilitate the development of 
pathologic implants in patients, including CC and BIA-
ALCL, to implement truly effective interventions.
To understand how bacteria influence the develop-
ment of breast implant-associated complications, it is 
critical to know which bacteria are present in a clinically 
benign scenario. However, data from this “negative con-
trol” group are scant, as evaluating normal breast implant 
colonization is challenging since it requires assessing 
either temporary TE38 or permanent implants explant-
ed at the time of less common revision surgery due to 
 malposition or when managing pathology on the contra-
lateral side. Of the few small studies that address this ques-
tion, Pajkos et al.4 identified bacteria in 1 of 8 (12.5%) 
clinically benign breast implants, Rieger et al.3 identified 
bacteria in 4 of 21 (19%) patients with Baker grade I and 
II capsules, and Hu et al.5 identified 7.6 × 105 bacteria/mg 
tissue in 3 clinically normal breast implants. Significantly, 
more bacteria were detected on pathologic implants than 
uncomplicated ones in these studies, suggesting bacterial 
abundance impacts the development of complications. 
The presence of bacteria on benign implants, though, re-
quires further study to determine whether bacterial spe-
Fig. 2. representative images of clinically normal and clinically complicated breast implants immuno-
fluorescently stained for fibrinogen and collagen. all devices imaged had no culturable bacteria. Stain-
ing revealed collagen (cn) and fibrinogen (Fg) were present on the majority of clinically uncomplicated 
(a and B) and clinically complicated (c and D) patient devices. controls are implant pieces treated the 
same but without primary antibody. commercially available primary antibodies: goat antifibrinogen 
(cat # F8512); rabbit anticollagen (cat. #234169, calbiochem).
Table 3. Breast Implants with Pathology without 
Detectable Bacteria Stained for Deposited Fibrinogen and 
Collagen
Patient 
No. Pathology Implant Surface Fibrinogen Collagen
10 CC TE Biocell 
texture
+ ˗
16 CC I Siltex 
texture
+ +
31 CC I Smooth + +










Table 4. Bacteria Can Be Detected on Clinically Normal 












2 TE/Biocell Collagen S. epi +
3 TE/Biocell Collagen S. epi +
4 TE/Biocell Collagen CNS +
5 TE/Biocell Collagen CNS +
9 Implant-Biocell Fibrinogen GBS +
23 TE/Biocell Fibrinogen K. pneum +
PRS Global Open • 2019
6
cies or strains, virulence factor production, or interactions 
with other bacteria or the host contribute to the develop-
ment of complications.19,24,39–41
While this study is not adequately designed or pow-
ered to compare the bacterial abundance between clini-
cally normal and complicated breast implants, it does 
provide important insights into the potential bacterial 
reservoir on uncomplicated devices. In this study, we de-
tected bacteria in 41% of the clinically normal breast im-
plants and/or surrounding capsules analyzed—a higher 
proportion of bacteria-positive, normal breast prostheses 
than previous reports.3–5 This is likely due to our combin-
Fig. 3. representative images of devices immunofluorescently stained for cultured bacteria and host 
proteins. a, group B streptococcus (gBS) was cultured from the Biocell-textured silicone breast implant 
of patient 9, which was clinically normal. gBS was detected via immunofluorescence staining and it co-
localized with the deposited host protein fibrinogen (Fg). Staphylococcus epidermidis (Se) was cultured 
from patient 22’s Biocell-textured silicone implant, which was clinically complicated by a double cap-
sule without seroma. Se was visible on the device and co-localized with collagen (cn). K. pneumoniae 
(KP) and Se were cultured from patients 23’s Biocell-textured te, which was clinically normal. KP (c) and 
Se (D) were both visible on the device and co-localized with deposited Fg and cn, respectively. controls 
were pieces of each device treated the same, but without primary antibody. commercially available 
primary antibodies: goat antifibrinogen (cat # F8512); rabbit anticollagen (cat. #234169, calbiochem); 
mouse anti-S. epidermidis (cat. # Ma1-35788, thermoFisher Scientific); rabbit anti-Pseudomonas (cat. # 
ab68538, abcam); rabbit anti-Protein a (for S. aureus) (P3775, Sigma-aldrich); rabbit antienterococcus 
(cat. # Pa1-73120); rabbit anti-Klebsiella,58 and rabbit antigroup B streptococcus.22,59 Secondary antibod-
ies: irDye 800cW donkey antigoat, irDye 800lt donkey antimouse, and irDye 680lt donkey antirabbit 
(li-cOr Biosciences).













Seroma (˗)ve Collagen S. epi +
25 TE/Biocell Infection Collagen CNS +
26 Implant/Biocell Double capsule, 
Seroma (+)ve
Collagen CNS +
29 Implant/smooth Double capsule, 
Seroma (+)ve
Collagen CNS +
30 Implant/Biocell CC Collagen S. epi +
 Walker et al. • Matrix Proteins and Bacteria on Breast Implants
7
ing  standard sonication and plating, similar to previous 
studies, with liquid culturing techniques, to detect low 
colonization levels and/or bacteria firmly adherent to the 
implant. Of the clinically normal implants that were bac-
teria-positive, all had a Biocell-textured surface and were 
colonized exclusively by Gram-positive bacteria, with CNS 
the chief microorganism identified. For clinically nor-
mal TE, all colonized devices also had Biocell-textured 
surfaces; however, Gram-negative bacteria, including K. 
pneumoniae and P. aeruginosa, were found in addition to 
Gram-positive microorganisms. The wider array of bacte-
ria present on TE may be due to the fact that the implant 
reconstruction paradigm differs significantly from aes-
thetic breast augmentation, with the traumatic dispersion 
of parenchymal and ductal bacteria from the breast and 
skin microbiome during mastectomy and reconstruction, 
longer operative times, and the potential for disease- or 
chemotherapy-induced immunosuppression.1,42 Recog-
nizing the greater likelihood for bacterial contamination 
following TE breast reconstruction,42 a higher incidence 
of bacterial contamination with a more diverse group of 
microbes is not unexpected. Notably, the routine use of 
betadine irrigation of the skin and postmastectomy pock-
et before insertion of a TE with acellular dermal matrix 
may have been sufficient to reduce the contaminating 
bacteria below a clinically problematic threshold in these 
patients.13,26 Interestingly, similarly to what we found for 
normal implants, only Gram-positive bacteria, and pri-
marily CNS, were found colonizing CC (50%) and dou-
ble capsule (40%) specimens. While we cannot discount 
that some of the patients with colonized, clinically normal 
devices would eventually go on to develop complications 
like infection or CC, future studies elucidating the host-
pathogen interactions that lead to pathologic implants 
will be critical for understanding why some women with 
colonized implants develop complications while others 
do not.
The presence of CNS, which are known skin coloniz-
ers, on both pathologic and benign implants supports 
the dogma that breast prosthesis contamination primarily 
occurs through contact with the skin microbiota during 
placement. However, even if skin contact can be mini-
mized,43,44 breast implants are still susceptible to bacteria 
that reside in the breast parenchyma, which also contain 
CNS, among other Gram-positive bacteria.6–10 Thus, the 
breast represents a clean-contaminated surgical site.9 Im-
portantly, the breast microbiome has greater microbial 
diversity than the skin,6 and is formed and evolved over 
time through the translocation of bacteria through mu-
cosal membranes of the gut, oropharynx, and urogenital 
tract.7,45,46 Recent evidence suggests that the composition 
of the breast microbiome varies based on depth of biopsy, 
suggesting the important contributions of the nipple and 
skin microbiome to bacteria within the breast.10 Given the 
proximity of a breast implant to the colonized breast pa-
renchyma, there is ample opportunity, even years past the 
time of initial device insertion, for bacteria to contact the 
implant surface and/or capsule. Thus, it is reasonable to 
expect that the bacteria contaminating implants is similar 
to the breast parenchyma microbiome because parenchy-
mal microbes have the most direct pathway to the implant 
surface after placement.
Our previous work detailing the molecular mecha-
nisms that result in catheter-associated urinary tract infec-
tions (CAUTI) has provided important insights into the 
host-pathogen interactions that facilitate disease and may 
lead to the development of therapeutics to treat these 
recalcitrant infections.18 This work showed that fibrino-
gen, which is recruited to the bladder following catheter-
induced damage to the urothelium, is deposited on the 
urinary catheter surface and provides a critical binding 
substrate for Enterococcus faecalis and S. aureus adherence 
and biofilm formation.18,22 By developing a vaccine that 
specifically blocked the ability of the adhesive tip of the 
E. faecalis Ebp pilus to interact with fibrinogen, we could 
effectively prevent and treat enterococcal CAUTI in a 
mouse model.22 Thus, by identifying bacterial virulence 
mechanisms and dissecting the host-pathogen interac-
tions that lead to CAUTI, it may be possible to design and 
develop effective therapeutics. Herein, we begin to trans-
late this work to the breast implant paradigm. We found 
that fibrinogen was deposited on 17/18 and collagen on 
13/18 of the breast implants analyzed in both clinically 
normal and abnormal cohorts (Tables 2, 3). Fibrinogen 
deposition likely stems from surgical manipulation of the 
breast parenchyma, which stimulates inflammation.47,48 
Importantly, the deposition of host proteins, including 
fibrinogen and collagen, on breast prostheses has impor-
tant implications for bacterial adherence and infection, 
as it is becoming increasingly clear that many bacteria 
encode proteins that bind to these factors to facilitate 
disease. Notably, we found that CNS co-localized with col-
lagen on explanted breast implants. S. epidermidis elabo-
rates SdrF49 and GehD, which interact with collagen,50 
thus providing a potential mechanism for S. epidermidis 
breast implant adherence or biofilm formation. Interest-
ingly, K. pneumoniae51 and Group B Strep52 that express pili 
that are reported to play an important roles in biofilm for-
mation19,53 co-localized with fibrinogen in our explanted 
implants. Together, these data provide important insights 
into potential targets for the development of nonantibio-
tic therapeutics, including small molecule inhibitors or 
vaccines that specifically block host-pathogen interactions 
that facilitate disease.24,40 Immediate next steps will in-
clude further characterization of matrix protein binding 
to various breast implant surfaces and the predilection of 
particular bacteria to them.
CONCLUSIONS
We readily detected bacteria and matrix protein depo-
sition on the smooth and textured surfaces of clinically 
normal and pathologic implants, explanted months to 
decades after insertion. Bacteria co-localized with matrix 
proteins, thus suggesting bacteria may preferentially ad-
here to host proteins instead of abiotic surfaces. Future 
studies examining bacteria-related breast implant pathol-
ogy should analyze a sufficient percentage of the implant 
surface to avoid sampling bias, and include an adequately 
powered control group. Finally, several knowledge gaps in 
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the field of breast implant bacteria require further study 
including identifying the signals, bacterial, or host, that 
trigger the transition from a normal, uncomplicated im-
plant to a pathologic state and the role of matrix proteins, 
like collagen and fibrinogen, in implant contamination. 
The answers to these questions may lead to the develop-
ment of novel nonantibiotic therapeutic strategies.
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